THX Pharma
ALTHX.PA · PAR
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | €0 | €0 | €2 | €0 |
| % Growth | -100% | -98.4% | 2,864.1% | – |
| Cost of Goods Sold | €0 | €1 | €1 | €3 |
| Gross Profit | -€0 | -€1 | €1 | -€3 |
| % Margin | – | -1,851.7% | 43.6% | -3,472.8% |
| R&D Expenses | €0 | €1 | €0 | €3 |
| G&A Expenses | €0 | €1 | €1 | €1 |
| SG&A Expenses | €2 | €1 | €1 | €1 |
| Sales & Mktg Exp. | €0 | €0 | €0 | €0 |
| Other Operating Expenses | -€1 | -€1 | €0 | -€2 |
| Operating Expenses | €1 | €1 | €1 | €1 |
| Operating Income | -€1 | -€2 | -€0 | -€4 |
| % Margin | – | -6,766.4% | -10.2% | -5,058.4% |
| Other Income/Exp. Net | €0 | €0 | €0 | €0 |
| Pre-Tax Income | -€1 | -€2 | -€0 | -€4 |
| Tax Expense | -€0 | -€0 | -€0 | -€1 |
| Net Income | -€1 | -€1 | €0 | -€3 |
| % Margin | – | -2,662.4% | 4.6% | -4,261.1% |
| EPS | -0.13 | -0.11 | 0.013 | -0.41 |
| % Growth | -18.2% | -946.2% | 103.2% | – |
| EPS Diluted | -0.13 | -0.11 | 0.013 | -0.41 |
| Weighted Avg Shares Out | 9 | 9 | 8 | 8 |
| Weighted Avg Shares Out Dil | 9 | 9 | 8 | 8 |
| Supplemental Information | – | – | – | – |
| Interest Income | €0 | €0 | €0 | €0 |
| Interest Expense | €0 | €0 | €0 | €0 |
| Depreciation & Amortization | €0 | €0 | €0 | €0 |
| EBITDA | -€1 | -€1 | -€0 | -€4 |
| % Margin | – | -3,355.8% | -8.1% | -4,875.7% |